NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients ...
Stocktwits on MSN
Why did CVS, URGN, CCK stocks hit 52-week highs today?
CVS Health reached a four-year high of $110.62 ahead of Q2 earnings, driven by retail upgrades and new healthcare services.
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient ...
Barchart on MSN
Short sellers are betting against UroGen Pharma stock, but Wall Street expects 263% earnings growth in 2027
UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum. ・URGN maintains a 100% “Buy ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Building on the growing body of clinical evidence supporting ZUSDURI and UGN-103, UroGen remains focused on advancing its proprietary RTGel technology and developing innovative therapies that have the ...
Transaction value based on SEC Form 4 weighted average purchase price ($27.30); post-transaction value based on the value of post-transaction holdings as reported in the Form 4. UroGen Pharma Ltd.
-- Results from this ongoing, noninterventional rollover study were presented at the 23rd Annual Society of Urological Oncology (SUO) Meeting in San Diego “LG-IR-NMIBC is a challenging disease to ...
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...
Mark Schoenberg's final disposition under a pre-established Rule 10b5-1 plan follows 191% annual returns, leaving him with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results